Status:
COMPLETED
Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD
Lead Sponsor:
Research in Real-Life Ltd
Collaborating Sponsors:
Teva Branded Pharmaceutical Products R&D, Inc.
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40-80 years
Brief Summary
The objective of this study is to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing chronic obstructive pulmonary disease (COPD) in primary care patients with evide...
Detailed Description
Current asthma guidelines in the UK are underpinned by evidence derived from randomised controlled trials (RCTs). Although RCT data are considered the gold standard, patients recruited to asthma RCTs ...
Eligibility Criteria
Inclusion
- Aged ≥40 years at index prescription date
- COPD diagnosis:
- diagnostic code, and
- ≥2 prescriptions for COPD therapy in baseline year (at different points in time)
- For the ICS increase cohort (i.e. IPDA) ≥1 of these prescriptions must be for ICS therapy.
- Commence ICS therapy at any time (even if before COPD diagnosis is made)
Exclusion
- \- A diagnostic read code for any other chronic respiratory disease (except asthma)
Key Trial Info
Start Date :
January 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
815377 Patients enrolled
Trial Details
Trial ID
NCT01141452
Start Date
January 1 2001
End Date
July 1 2007
Last Update
March 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Practice Research Database
London, London, United Kingdom, SW8 5NQ